Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 65175
1. García-Gómez MC, de Lama E, Ordoñez-Palau S, Nolla JM, Corbella E, Pintó X: High Prevalence of Gallstone Disease in Rheumatoid Arthritis: A New Comorbidity Related to Dyslipidemia? Reumatol Clin; 2017 Aug 01;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High Prevalence of Gallstone Disease in Rheumatoid Arthritis: A New Comorbidity Related to Dyslipidemia?
  • OBJECTIVE: To assess the prevalence of gallstone disease and identify associated risk factors in rheumatoid arthritis (RA) patients compared to the general population.
  • METHODS: Eighty-four women with rheumatoid arthritis were included in the study.
  • The prevalence of gallstone disease in rheumatoid arthritis was compared with data from a study of the Spanish population matched by age groups.
  • RESULTS: Twenty-eight of the 84 women had gallstone disease (33.3%).
  • RA women with and without gallstone disease were similar in most of the variables assessed, except for older age and menopausal status in the former.
  • A greater prevalence of gallstone disease was seen in rheumatoid arthritis patients compared to the general population of the same age; however, the differences were significant only in women aged 60 or older (45.5% versus 23.1% respectively, P-value .008).
  • The age-adjusted OR of developing gallstone disease in RA women compared with general population women was 2,3 (95% CI: 1.3-4.1).
  • A significantly higher HDL3-c subfraction and higher apoA-I/HDL and HDL3-c/TC ratios were observed in patients with gallstone disease.
  • CONCLUSION: Women with rheumatoid arthritis may have a predisposition to gallstones that can manifest in middle or older age compared with women in the general population.
  • This situation could be related to chronic inflammation and HDL metabolism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.
  • (PMID = 28778575.001).
  • [ISSN] 1885-1398
  • [Journal-full-title] Reumatologia clinica
  • [ISO-abbreviation] Reumatol Clin
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Artritis reumatoide / Cholecystectomy / Colecistectomía / Comorbidity / Comorbilidad / Gallstones / Lipids / Lipoproteins / Lipoproteínas / Litiasis biliar / Lípidos / Rheumatoid arthritis
  •  go-up   go-down


2. Li YP, Wu S, Ran A, Xu DY, Wei JM, Zhao ZL: <i>ARISTOLOCHIA BRACTEOLATE</i> RETZ. ATTENUATES HYPERURICEMIA IN A METABOLIC ARTHRITIS RAT MODEL. Afr J Tradit Complement Altern Med; 2017;14(4):180-187
MedlinePlus Health Information. consumer health - Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] <i>ARISTOLOCHIA BRACTEOLATE</i> RETZ. ATTENUATES HYPERURICEMIA IN A METABOLIC ARTHRITIS RAT MODEL.
  • The target of the research envisaged was to elucidate the activity of <i>A. bracteolata</i> extract on hyperuricemic condition in arthritis rat model.
  • Potassium oxonate was injected intra-articularly to produce arthritis.
  • The hyperuricemic effect, of <i>A. bracteolate</i> was analyzed by studying levels of uric acid in serum as well as in urine of arthritis induced rats.
  • CONCLUSION: The crude extract of <i>A. bracteolate</i> can be used to reduce hyperuricemia in metabolic arthritis produced in rat model, without inducing any potential damaging effects.
  • [MeSH-major] Aristolochia / chemistry. Arthritis / drug therapy. Hyperuricemia / drug therapy. Plant Extracts / administration & dosage

  • Genetic Alliance. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 2008;40(1):9-13 [17300978.001]
  • [Cites] Biol Pharm Bull. 2007 Aug;30(8):1551-6 [17666819.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2262-71 [16886064.001]
  • [Cites] J Am Soc Nephrol. 2008 Jun;19(6):1204-11 [18337481.001]
  • [Cites] Pharmacol Res Commun. 1975 Apr;7(2):117-24 [1144488.001]
  • [Cites] Circ J. 2005 Aug;69(8):928-33 [16041161.001]
  • [Cites] Curr Opin Rheumatol. 2002 May;14(3):281-6 [11981327.001]
  • [Cites] Dtsch Med Wochenschr. 2001 Nov 23;126(47):1331-4 [11719858.001]
  • [Cites] Drugs. 2004;64(21):2399-416 [15481999.001]
  • [Cites] Am J Kidney Dis. 2004 Oct;44(4):642-50 [15384015.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1193-226 [10508233.001]
  • [Cites] J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S165-8 [17130256.001]
  • [Cites] J Ethnopharmacol. 2004 Jul;93(1):133-40 [15182918.001]
  • [Cites] N Engl J Med. 2003 Oct 23;349(17):1647-55 [14573737.001]
  • [Cites] Phytomedicine. 2003;10(6-7):558-62 [13678243.001]
  • [Cites] J Am Soc Nephrol. 2005 Jan;16(1):133-43 [15574513.001]
  • [Cites] J Biol Chem. 1998 Oct 30;273(44):28670-6 [9786861.001]
  • [Cites] Kidney Int. 2000 Oct;58(4):1389-99 [11012874.001]
  • [Cites] Hypertens Res. 2001 Nov;24(6):691-7 [11768729.001]
  • [Cites] Arthritis Rheum. 2002 Dec 15;47(6):610-3 [12522834.001]
  • [Cites] Biol Pharm Bull. 2005 Dec;28(12):2231-4 [16327155.001]
  • [Cites] Curr Hypertens Rep. 2006 May;8(2):120-4 [16672144.001]
  • [Cites] Life Sci. 2000 Apr 14;66(21):2051-70 [10823345.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 May;25(5):1038-44 [15746438.001]
  • [Cites] Planta Med. 2002 Feb;68(2):175-8 [11859475.001]
  • (PMID = 28638881.001).
  • [ISSN] 2505-0044
  • [Journal-full-title] African journal of traditional, complementary, and alternative medicines : AJTCAM
  • [ISO-abbreviation] Afr J Tradit Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Plant Extracts; 268B43MJ25 / Uric Acid; AYI8EX34EU / Creatinine; K7Q1JQR04M / Dinoprostone
  • [Keywords] NOTNLM ; Aristolochia bracteolate / Hyperuricemia / arthritis / rat model
  •  go-up   go-down


3. Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M: Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Manag Care Spec Pharm; 2017 Aug;23(8):859-867
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
  • The impact of these services on patient adherence to adalimumab and direct medical costs associated with autoimmune disease has not been assessed.
  • The sample included patients aged ≥ 18 years with a diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis who were biologic-naïve before initiation of adalimumab.
  • Patients who enrolled in the PSP (PSP cohort) were matched to those who did not enroll (non-PSP cohort) based on age, sex, year of treatment initiation, comorbidities, diagnosis, and initiation at a specialty pharmacy.
  • Medical costs for emergency department, inpatient, physician, and outpatient visits (all-cause and disease-related) and total costs (medical plus drug costs) were compared at 12 months following the index date using t-tests.
  • Disease-related medical costs were 22% lower for PSP than for non-PSP patients ($8,001 vs. $10,202; P = 0.045).
  • CONCLUSIONS: Patient enrollment in the PSP was associated with greater adherence, improved persistence, and reduced medical (all-cause and disease-related) and total health care costs for patients receiving adalimumab therapy.
  • Impact of AbbVie's patient support program on resource costs in Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis.
  • 2015;21(Suppl 4a):S74-75 (poster presentation at Academy of Managed Care, 27th Annual Meeting and Expo; April 7-10, 2015; San Diego, CA) and as abstract 2339 in Arthritis Rheumatol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28737994.001).
  • [ISSN] 2376-1032
  • [Journal-full-title] Journal of managed care & specialty pharmacy
  • [ISO-abbreviation] J Manag Care Spec Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Zhao P, Chen KL, Zhang GL, Deng GR, Li J: Pharmacological Basis for Use of &lt;i&gt;Selaginella moellendorffii&lt;/i&gt; in Gouty Arthritis: Antihyperuricemic, Anti-Inflammatory, and Xanthine Oxidase Inhibition. Evid Based Complement Alternat Med; 2017;2017:2103254

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological Basis for Use of <i>Selaginella moellendorffii</i> in Gouty Arthritis: Antihyperuricemic, Anti-Inflammatory, and Xanthine Oxidase Inhibition.
  • This study was aimed at evaluating the effects of <i>Selaginella moellendorffii</i> Hieron. (SM) on gouty arthritis and getting an insight of the possible mechanisms.
  • The paw oedema, the neutrophil accumulation, inflammatory mediators, lipid peroxidation, and histopathological changes of the joints were analyzed in gouty arthritis rat model, and the kidney injury and serum urate were detected in hyperuricemic mice.
  • The high dose of SM extract could significantly prevent the paw swelling, reduce gouty joint inflammatory features, reduce the release of IL-1<i>β</i> and TNF-<i>α</i>, lower malondialdehyde (MDA) and myeloperoxidase (MPO) levels, and increase superoxide dismutase (SOD) level (<i>P</i> < 0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1093-103 [15014182.001]
  • [Cites] Pain. 1987 Mar;28(3):379-93 [3574965.001]
  • [Cites] Immunol Rev. 2010 Jan;233(1):218-32 [20193002.001]
  • [Cites] Inflammation. 2011 Jun;34(3):184-92 [20495860.001]
  • [Cites] Nat Rev Rheumatol. 2010 Jan;6(1):30-8 [20046204.001]
  • [Cites] Zhongguo Zhong Yao Za Zhi. 2005 Oct;30(19):1507-10 [16335819.001]
  • [Cites] Anticancer Agents Med Chem. 2015;15(6):728-35 [25738871.001]
  • [Cites] Fitoterapia. 2010 Jun;81(4):253-8 [19775597.001]
  • [Cites] J Nutr. 2009 Jun;139(6):1095-102 [19403720.001]
  • [Cites] Fitoterapia. 2007 Dec;78(7-8):598-9 [17582697.001]
  • [Cites] J Clin Invest. 1993 Oct;92(4):1722-9 [7691884.001]
  • [Cites] N Engl J Med. 2011 Feb 3;364(5):443-52 [21288096.001]
  • [Cites] Free Radic Biol Med. 2009 Sep 1;47(5):616-21 [19500663.001]
  • [Cites] Crit Rev Food Sci Nutr. 2015 Jul 15;:0 [26176651.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2400-14 [15334451.001]
  • [Cites] Curr Opin Rheumatol. 2007 Mar;19(2):146-50 [17278929.001]
  • [Cites] Planta Med. 1999 Jun;65(5):465-7 [10418340.001]
  • [Cites] J Leukoc Biol. 2001 Oct;70(4):659-68 [11590204.001]
  • [Cites] Int J Nephrol Renovasc Dis. 2010;3:145-66 [21694941.001]
  • [Cites] Ann Rheum Dis. 2012 Nov;71(11):1765-70 [22863577.001]
  • [Cites] Arthritis Res Ther. 2006;8 Suppl 1:S3 [16820042.001]
  • [Cites] Nat Rev Rheumatol. 2014 May;10(5):271-83 [24614592.001]
  • [Cites] BMC Complement Altern Med. 2015 Apr 25;15:131 [25906842.001]
  • [Cites] Phytomedicine. 2011 May 15;18(7):561-6 [21144719.001]
  • [Cites] J Mol Evol. 1992 Jan;34(1):78-84 [1556746.001]
  • [Cites] J Leukoc Biol. 1997 Oct;62(4):444-9 [9335313.001]
  • [Cites] Food Chem Toxicol. 2010 Jan;48(1):229-35 [19819286.001]
  • [Cites] Arthritis Res Ther. 2011;13(5):R164 [21992185.001]
  • [Cites] J Nat Prod. 1998 Jan;61(1):71-6 [9461655.001]
  • (PMID = 28250791.001).
  • [ISSN] 1741-427X
  • [Journal-full-title] Evidence-based complementary and alternative medicine : eCAM
  • [ISO-abbreviation] Evid Based Complement Alternat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Curtis JR, Schulze-Koops H, Takiya L, Mebus CA, Terry KK, Biswas P, Jones TV: Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol; 2017 May-Jun;35(3):390-400
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
  • OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).
  • [MeSH-major] Antirheumatic Agents / administration & dosage. Arthritis, Rheumatoid / drug therapy. Piperidines / therapeutic use. Protein Kinase Inhibitors / administration & dosage. Pyrimidines / therapeutic use. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28079500.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Piperidines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Pyrroles; 87LA6FU830 / tofacitinib; EC 2.7.10.2 / Janus Kinases
  •  go-up   go-down


6. Kokkonen H, Stenlund H, Rantapää-Dahlqvist S: Cardiovascular risk factors predate the onset of symptoms of rheumatoid arthritis: a nested case-control study. Arthritis Res Ther; 2017 Jun 30;19(1):148
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular risk factors predate the onset of symptoms of rheumatoid arthritis: a nested case-control study.
  • BACKGROUND: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular disease (CVD).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Res Ther. 2015 Oct 12;17:284 [26458977.001]
  • [Cites] Diabetes Res Clin Pract. 2014 Dec;106(3):e90-2 [25451899.001]
  • [Cites] Arthritis Res Ther. 2016 Jan 28;18:33 [26818851.001]
  • [Cites] Rheumatology (Oxford). 2008 Sep;47(9):1286-98 [18467370.001]
  • [Cites] Glob Health Action. 2012 Dec 17;5:1-9 [23528041.001]
  • [Cites] J Rheumatol. 1999 Dec;26(12):2562-71 [10606363.001]
  • [Cites] Lancet. 2001 Dec 15;358(9298):2026-33 [11755609.001]
  • [Cites] Glob Health Action. 2010 Mar 22;3:null [20339479.001]
  • [Cites] Glob Health Action. 2012 Jan;5(1):19166 [28140848.001]
  • [Cites] Scand J Public Health Suppl. 2003;61:9-17 [14660242.001]
  • [Cites] Eur Heart J. 2009 Sep;30(17):2137-46 [19520708.001]
  • [Cites] Arthritis Res Ther. 2015 Mar 29;17:86 [25890172.001]
  • [Cites] Scand J Rheumatol. 2014;43(4):259-64 [24689997.001]
  • [Cites] Circulation. 2003 Mar 11;107(9):1303-7 [12628952.001]
  • [Cites] PLoS One. 2016 Jun 16;11(6):e0157360 [27310259.001]
  • [Cites] Ann Rheum Dis. 2008 Jan;67(1):64-9 [17517756.001]
  • [Cites] Ann Rheum Dis. 2014 Jan;73(1):219-26 [23505230.001]
  • [Cites] Arthritis Rheum. 2009 Oct;60(10):2861-9 [19790058.001]
  • [Cites] Atherosclerosis. 2015 Jul;241(1):211-8 [25670232.001]
  • [Cites] Arthritis Res Ther. 2016 Nov 29;18(1):277 [27894341.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):402-11 [15693010.001]
  • [Cites] Ann Rheum Dis. 2009 Sep;68(9):1395-400 [18697775.001]
  • [Cites] N Engl J Med. 2012 Jan 26;366(4):321-9 [22276822.001]
  • [Cites] Lancet. 2003 Mar 1;361(9359):777-80 [12620753.001]
  • [Cites] Mol Cell Endocrinol. 2015 Feb 15;402:113-9 [25578600.001]
  • [Cites] Arthritis Rheum. 2008 Dec 15;59(12):1690-7 [19035419.001]
  • [Cites] Ann Rheum Dis. 2012 Sep;71(9):1524-9 [22425941.001]
  • [Cites] Lancet. 2008 Jul 19;372(9634):224-33 [18640459.001]
  • [Cites] Ann Rheum Dis. 2010 Jul;69(7):1310-4 [19854708.001]
  • [Cites] Rheumatology (Oxford). 2004 Jun;43(6):731-6 [15014200.001]
  • [Cites] J Intern Med. 2010 Dec;268(6):578-85 [20698926.001]
  • [Cites] Ann Rheum Dis. 2007 Feb;66(2):184-8 [16760255.001]
  • [Cites] Arthritis Res Ther. 2011 Aug 15;13(4):R131 [21843325.001]
  • (PMID = 28666478.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Apolipoproteins / Body mass index / Cardiovascular disease / Diabetes mellitus / Rheumatoid arthritis / Smoking
  •  go-up   go-down


7. Brogan DM, van Hogezand RM, Babovic N, Carlsen B, Kakar S: The Effect of Metacarpophalangeal Joint Hyperextension on Outcomes in the Surgical Treatment of Carpometacarpal Joint Arthritis. J Wrist Surg; 2017 Aug;6(3):188-193
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Effect of Metacarpophalangeal Joint Hyperextension on Outcomes in the Surgical Treatment of Carpometacarpal Joint Arthritis.
  • <b>Purpose</b>  In the surgical treatment of thumb carpometacarpal (CMC) joint arthritis, the effect of mild preoperative metacarpophalangeal (MCP) hyperextension on postoperative functional outcomes is unknown.
  • We sought to examine outcomes after surgical treatment of CMC arthritis in patients with and without mild preexisting MCP deformity.
  • <b>Methods</b>  A retrospective review was conducted to analyze the functional outcomes of patients treated for CMC arthritis at a single institution from March 1998 to May 2009.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tech Hand Up Extrem Surg. 2011 Jun;15(2):119-24 [21606786.001]
  • [Cites] J Hand Surg Br. 1988 Nov;13(4):421-5 [3249143.001]
  • [Cites] Hand Clin. 2001 May;17 (2):255-60 [11478047.001]
  • [Cites] J Hand Surg Am. 2012 Apr;37(4):837-8 [22305730.001]
  • [Cites] J Hand Surg Am. 1999 Jul;24(4):786-98 [10447171.001]
  • [Cites] J Hand Surg Am. 1998 Jul;23 (4):607-11 [9708373.001]
  • [Cites] J Bone Joint Surg Am. 1979 Sep;61(6A):903-5 [479238.001]
  • [Cites] J Hand Surg Eur Vol. 2011 May;36(4):280-4 [21372052.001]
  • [Cites] J Bone Joint Surg Am. 1976 Jul;58(5):667-70 [932064.001]
  • [Cites] Osteoarthritis Cartilage. 2006 May;14 (5):496-500 [16545585.001]
  • [Cites] Orthop Traumatol Surg Res. 2009 Sep;95(5):352-8 [19643692.001]
  • [Cites] J Hand Surg Am. 1986 May;11(3):324-32 [3711604.001]
  • [Cites] J Bone Joint Surg Am. 1963 Dec;45:1654-62 [14083140.001]
  • [Cites] Osteoarthritis Cartilage. 2006 Sep;14 (9):953-7 [16759885.001]
  • [Cites] Hand Clin. 2008 Aug;24(3):295-9, vii [18675721.001]
  • [Cites] Clin Orthop Relat Res. 2013 Dec;471(12 ):3738-44 [23959907.001]
  • [Cites] J Hand Surg Am. 2011 Jan;36(1):170-82 [21193137.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:266-76 [16131901.001]
  • [Cites] J Hand Surg Am. 1988 May;13(3):449-53 [3379288.001]
  • (PMID = 28725499.001).
  • [ISSN] 2163-3916
  • [Journal-full-title] Journal of wrist surgery
  • [ISO-abbreviation] J Wrist Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; CMC joint arthritis / MCP joint hyperextension / outcomes
  •  go-up   go-down


8. Becciolini M, Bonacchi G, Becciolini A: Sonographic findings in a case of cactus thorn arthritis. J Clin Ultrasound; 2017 May;45(4):240-241

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic findings in a case of cactus thorn arthritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28164317.001).
  • [ISSN] 1097-0096
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


9. Machado SH, Xavier RM: Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf; 2017 Apr;16(4):493-500
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
  • INTRODUCTION: Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody and IL-6 receptor antagonist, currently approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) in children aged 2 years or older refractory to conventional treatment.
  • [MeSH-major] Antibodies, Monoclonal, Humanized / therapeutic use. Antirheumatic Agents / therapeutic use. Arthritis, Juvenile / drug therapy

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28277841.001).
  • [ISSN] 1744-764X
  • [Journal-full-title] Expert opinion on drug safety
  • [ISO-abbreviation] Expert Opin Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Receptors, Interleukin-6; I031V2H011 / tocilizumab
  • [Keywords] NOTNLM ; IL-6 inhibitors (major topic) / juvenile idiopathic arthritis (major topic) / safety (major topic) / treatment (major topic)
  •  go-up   go-down


10. Yu JS, Moon E, Kim KH: A new cerebroside from the twigs of Lindera glauca (Sieb. et Zucc.) Blume. Bioorg Chem; 2017 10;74:122-125
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ) Blume (Lauraceae) has been used to treat rheumatic arthritis, stroke, and cardiac pain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28778013.001).
  • [ISSN] 1090-2120
  • [Journal-full-title] Bioorganic chemistry
  • [ISO-abbreviation] Bioorg. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cerebrosides; 0 / Lipopolysaccharides; 31C4KY9ESH / Nitric Oxide
  • [Keywords] NOTNLM ; Anti-inflammation (major topic) / Cerebroside (major topic) / Lauraceae (major topic) / Lindera glauca (major topic) / NO (major topic)
  •  go-up   go-down






Advertisement